Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Frederich

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Diabetologia|April 3, 2020
Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trialsDavid Z I Cherney, Hiddo J L Heerspink, Robert Frederich, et al.
Diabetes Care|March 12, 2015
Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trialLawrence A Leiter, Hwee Teoh, Eugene Braunwald, et al.
Circulation|October 7, 2020
Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV TrialFrancesco Cosentino, Christopher P Cannon, David Z I Cherney, et al.
The New England Journal of Medicine|September 23, 2020
Cardiovascular Outcomes with Ertugliflozin in Type 2 DiabetesChristopher P Cannon, Richard Pratley, Samuel Dagogo-Jack, et al.
Diabetes, Obesity & Metabolism|May 23, 2022
Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitusMatthew W Segar, Ahmed A Kolkailah, Robert Frederich, et al.
Circulation|September 6, 2014
Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trialBenjamin M Scirica, Eugene Braunwald, Itamar Raz, et al.
The New England Journal of Medicine|September 3, 2013
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitusBenjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, et al.
Diabetes Care|January 2, 2015
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 TrialJacob A Udell, Deepak L Bhatt, Eugene Braunwald, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|February 9, 2026
Post-authorization safety study to assess the risk of diabetic ketoacidosis among type 2 diabetes mellitus patients treated with ertugliflozin compared to patients treated with other antihyperglycaemic agents in a Medicare and Medicaid populationAshish Rai, James Marshall, Sampada Nandyala, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Diabetologia|April 3, 2020
Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trialsDavid Z I Cherney, Hiddo J L Heerspink, Robert Frederich, et al.
Diabetes Care|March 12, 2015
Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trialLawrence A Leiter, Hwee Teoh, Eugene Braunwald, et al.
Circulation|October 7, 2020
Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV TrialFrancesco Cosentino, Christopher P Cannon, David Z I Cherney, et al.
The New England Journal of Medicine|September 23, 2020
Cardiovascular Outcomes with Ertugliflozin in Type 2 DiabetesChristopher P Cannon, Richard Pratley, Samuel Dagogo-Jack, et al.
Diabetes, Obesity & Metabolism|May 23, 2022
Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitusMatthew W Segar, Ahmed A Kolkailah, Robert Frederich, et al.
Circulation|September 6, 2014
Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trialBenjamin M Scirica, Eugene Braunwald, Itamar Raz, et al.
The New England Journal of Medicine|September 3, 2013
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitusBenjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, et al.
Diabetes Care|January 2, 2015
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 TrialJacob A Udell, Deepak L Bhatt, Eugene Braunwald, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|February 9, 2026
Post-authorization safety study to assess the risk of diabetic ketoacidosis among type 2 diabetes mellitus patients treated with ertugliflozin compared to patients treated with other antihyperglycaemic agents in a Medicare and Medicaid populationAshish Rai, James Marshall, Sampada Nandyala, et al.
Pageof 4